学科与关键词
关键词
savolitinibEGFRmNSCLC
- A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 MutationLu, S.; Yu, Y.; Guo, Q.; Li, Y.; Zhong, D.; Gu, L.; Fang, J.; Han, S.; Pan, P.; Deng, P.; Liu, B.; Wang, M.; Wu, H.; Gao, F.; Lin, W.; Li, J.; Lv, D.; He, S.; Liu, Z.; Pan, C.; Li, J.; Tian, Y.; Yang, N.; Zhang, Y.; Liu, C.; Zhu, X.; Song, Q.; Yu, J.; Fan, S.; Ren, Y.; Shi, M.; Su, W.被引 1
- Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLCLu, S.; Fang, J.; Li, X.; Cao, L.; Zhou, J.; Guo, Q.; Liang, Z.; Cheng, Y.; Jiang, L.; Yang, N.; Han, Z.; Shi, J.; Chen, Y.; Xu, H.; Zhang, H.; Chen, G.; Ma, R.; Sun, S.; Fan, Y.; Weiguo, S.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 6
- Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinibZhang, Li; Wang, Yongsheng; Lin, Lizhu; Yu, Yongfeng; Lu, Shun*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231216089.
